Inhibrx Biosciences stock: Ozekibart posts 62.7% response rate

CEO Mark Lappe buys 10,040 shares in Inhibrx Biosciences ...
Inhibrx Biosciences stock falls 1.62 percent on October ...
Inhibrx updates pipeline data as analysts rate Inhibrx stock ...
Inhibrx Biosciences Shares Surge on Clinical Breakthrough ...